Syngeneic models to test novel strategies enhancing the efficacy of anti-CTLA4 antibody therapies

    • Model features: intact immune system, responding & non-responding models
    • Tumor cell lines:  Breast Cancer (4T1, EMT6), Colon Cancer (CT26, MC38), Gliobastoma (GL261), Lung Cancer (LLC1), Pancreatic cancer (Pan02), Renal Cancer (Renca), Sarcoma (MCA205)
    • Tumor implantation: subcutaneous or orthotopic
    • Robust treatment protocol in line with published literature data.
    • Readouts: body weight, tumor size, survival
Syngeneic models anti-CTLA4 mab cancer immunotherapy immune checkpoint inhibitors CRO services

Differential CTLA4 blockade efficacy in different syngeneic mouse models CTLA4 blockade enhances survival of CT26, slightly that of GL261, but not that of 4T1 tumor-bearing mice. Mice are challenged with respective tumor cells and exposed to anti-CTLA4 antibody. In the CT26 responding model, anti-CTLA4 treatment significantly improves mouse survival. (sc, subcutaneous ; ot, orthotopic)

In vivo efficacy & mechanism of action studies for novel immunotherapies

in vivo efficacy study CRO breast cancer

Straightforward in vivo efficacy studies

  • N=10: Standard groups of 10 mice including groups exposed to test compound alone and in combination with reference therapy.
  • Weekly reports: monitoring tumor growth, body weight, and survival
in vivo cancer immunotherapy studies CRO services

Flexible sampling options

  • Monitoring response over time: satellite mice, serial bleeding, intra-tumoral biopsies
  • On-demand sample collection: blood, serum, plasma, tumor, organ samples
in vivo mechanism actin immunotherapy breast cancer

A flexible platform to quantify tumor-microenvironment & peripheral markers

  • Multiplex immunophenotyping by flow cytometry & digital pathology
  • Spatial transcriptomics & proteomics

Immune profiling of CT26 syngeneic colon cancer model to anti-CTLA4 therapy

Immune profiling of CT26 tumor-bearing model to anti-CTLA4 therapy

RT-qPCR analysis of key immune markers encoding genes in CT26 tumor-bearing model of anti-CTLA4 therapy. CTLA4 blockade modulates Th17-related encoding genes in TDLNs, including Rorc, Il17a and Il6.

immune profiling anti-CTLA4 immunotherapy-syngeneic mouse-model CRO in vivo services

Higher immune cell infiltration upon anti-CTLA4 therapy

Flow cytometry analysis of CT26 tumors highlights a higher immune cell infiltration within the tumor upon CTLA4 blockade. Anti-CTLA4 antibody treatment of CT26-tumor bearing mice leads to a higher number of Tumor infiltrating lymphocytes (CD45+). This feature is associated with an increase in T cells (CD3+) and particularly with an accumulation of effector T cells (CD8+). In contrast, CD4+ T cells infiltration of the tumor is decreased upon treatment.

tumor infiltrate flow cytometry anti-CTLA-4 antibody syngeneic model CRO immuno-oncology services

Analysis of key immune markers encoding genes by RT-qPCR.

TDLN (Tumor Draining Lymph Nodes) and CD11c + dendritic cells from CT26 tumor bearing mice exposed to anti-CTLA4 antibody or only exposed to vehicle were analyzed by RT-qPCR for specific immune markers. Results show that anti-CTLA4 exposure induces an up-regulation of Il6 and Il17 in TDLN while an icrease in Ifng and Pdl2 is observed in dendritic cells.

RT-qPCR immune markers syngeneic models anti-CTLA4 inhibitor

Why working with Explicyte?

in Immuno-Oncology

  • 150+ in vivo campaigns conducted over the past 10 years
  • 20+ peer-reviewed publications in key immuno-oncology journals
  • Bespoke study designs based on client objectives and literature


  • A dedicated study director (PhD level) from experimental plan to final report
  • Weekly reports to provide regular updates & adapt experimental strategy
  • Comprehensive analytical platform to decipher anti-tumor response

Your contacts

explicyte team 2024

Talk to our team ! Your key contacts:

Study directors: Paul Marteau, PharmD (not on picture), Jean-Philippe Guégan, PhD Leadership: Imane Nafia, PhD (CSO), Alban Bessede, PhD (founder, CEO), Loic Cerf, MSc (COO)

Tell us about your project !

    Select department:

    In Vivo Models Of CTLA-4 Blockade I Immuno-Oncology CRO services

    As monotherapy, CTLA-4 immune checkpoint blockade installs a long-lasting anti-tumor immunity in a small fraction of patients. To assess new drugs for their capacity to improve the benefit of CTLA-4 modulators, we offer syngeneic tumor-bearing mouse models with well-characterized responses to an anti-CTLA-4 monoclonal antibody. Our models include both CTLA-4 inhibition responding and non-responding models. They enable the evaluation of novel compounds capable of enhancing the efficacy of anti-CTLA-4 antibodies and the study of predictive biomarkers to select anti-CTLA-4 responders.

    WordPress Lightbox